The liquid biopsy test uses circulating tumor DNA to support therapy selection, trial matching, and monitoring—even when tissue is limited.
NeoGenomics Inc, a provider of oncology diagnostic solutions that enable precision medicine, announced the launch of NEO PanTracer LBx, a blood-based comprehensive genomic profiling test, expanding the company’s PanTracer portfolio.
PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring to empower data-driven decisions even when tumor tissue is limited or unavailable.
“The launch of our liquid biopsy test positions us at the forefront of the precision oncology market,” says Tony Zook, chief executive officer of NeoGenomics, in a release. “As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It’s a strategic milestone that underscores our commitment to sustainable growth and clinical leadership.”
Using circulating tumor DNA from a blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver actionable insights.
When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring.
